Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

302 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents

NCT00542750

Cannabis Dependence

COMPLETED PHASE1/PHASE2

N-Acetylcysteine for Youth Cannabis Use Disorder

NCT03055377

Cannabis Use Disorder

COMPLETED PHASE2/PHASE3

Cannabis Use and Relapse After One Week of Contingency Management Therapy

NCT04202146

Cannabis Dependence

COMPLETED NA

Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use

NCT07011615

Cannabis Use

RECRUITING NA

Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents

NCT03276221

Cannabis Use Cognitive Change Adolescent Behavior

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this Phase 3 study is to evaluate the impact of NAC 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50). After assessment and inclusion into the study, participants will be randomized to receive a 12-week course of NAC 1200 mg or matched placebo twice daily. All participants will concurrently participate in a twice-weekly contingency management (CM) intervention. Medication management will be conducted weekly throughout treatment by the medical clinician. Urine cannabinoid testing will occur at all visits, and will be used as the primary determinant of cannabis use. Participants will return approximately four weeks after treatment conclusion for evaluation of adverse events with medication discontinuation and sustained treatment effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NAC plus CM

N-acetylcysteine (NAC) plus Contingency Management (CM)

Group Type ACTIVE_COMPARATOR

N-Acetylcysteine

Intervention Type DRUG

Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Placebo plus CM

Placebo plus Contingency Management (CM)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

N-Acetylcysteine

Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Intervention Type DRUG

Placebo

Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NAC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-50 years
* Must be able to understand the study and provide written informed consent
* Must meet current DSM-IV criteria for cannabis dependence in the last 30 days
* Must express interest in treatment for cannabis dependence
* Must submit a positive urine cannabinoid test during screening
* Women of child bearing potential must agree to use appropriate birth control methods during study participation: oral contraceptives, contraceptive patch, barrier (diaphragm or condom), levonorgestrel implant, medroxyprogesterone acetate, complete abstinence from sexual intercourse, or hormonal contraceptive vaginal ring

Exclusion Criteria

* Allergy or intolerance to N-Acetylcysteine
* Women who are pregnant or lactating
* Current use of NAC or any supplement containing N-Acetylcysteine (must agree not to take any such supplement throughout study participation)
* Use of carbamazepine or nitroglycerin within 14 days of randomization
* Current enrollment in treatment for cannabis dependence
* Any use of synthetic cannabinoids (such as K2/Spice) in the 30 days prior to screening or during the period between screening and randomization
* Current substance dependence, other than cannabis or nicotine
* Urine drug screen positive for any drug of abuse other than cannabis or amphetamines at the randomization visit (Only participants who have a valid prescription for amphetamines (e.g., for ADHD) may be included)
* Urine drug screen positive for amphetamines at the randomization visit without having a valid prescription for it
* Maintenance treatment with buprenorphine or methadone
* Recent history of asthma (within the last 3 years)
* History of seizure disorder, bipolar disorder, schizophrenia, or other significant or unstable medical or psychiatric illness that may place the participant at increased risk in the judgment of the medical clinician
* Significant risk of homicide or suicide

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No